Category Archives: BioUtah News
Merit Medical Acquires Biolife Delaware
Acquired business offers the StatSeal® and WoundSeal® products, which provide hemostasis solutions that complement the wide range of procedures Merit’s portfolio supports. Acquisition projected to add approximately $18 million of revenue, on an annualized basis beginning in fiscal year 2026, with a mid-teens growth and accretive non-GAAP margin and profitability profile Merit reaffirms full-year 2025 […]
Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies
New BD FACSDiscover™ A8 Cell Analyzer Brings Leading-Edge Capabilities to Wider Range of Scientists across Academia and Biopharma
KyphoLift Debuts at ISMRM 2025: Transforming Patient Positioning for Safer, More Accurate Imaging
Visit ISMRM Booth H19 for Hands-On Demonstrations of the KyphoLift™ and KyphoWedge™ Systems
Kelvyn Cullimore: An Unfair Penalty on Life-Saving Pills
BioUtah president and CEO, Kelvyn Cullmore, recently penned an op-ed published in the Deseret News.
Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis
The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients.
Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial
In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months.
Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology
Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk
EDWARDS TAVR RECEIVES FDA APPROVAL FOR PATIENTS WITH ASYMPTOMATIC SEVERE AORTIC STENOSIS
Transforming Care for Severe AS Patients
Thermo Fisher Scientific Leverages Integrated Solutions to Accelerate the Development of Biologic Therapeutics
Enhanced platform technology and the addition of a robust, high-quality CHO K-1 cell line decreases lead time to Investigational New Drug (IND)
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting
Podium presentation showcases the clinical application of Precise™ MRD
Biologic Input Output Systems (BIOS) Appoints Chris Duncan, MD as Chief Medical Officer to Drive Clinical Innovation
Renowned neuroprosthetics expert joins BIOS to lead clinical strategy and advance development of the Universal Neural Interface.
